Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis To Launch Exforge In September 2007

This article was originally published in The Pink Sheet Daily

Executive Summary

Company cannot market the hypertension combination drug until expiration of exclusivity for Pfizer’s Norvasc.
Advertisement

Related Content

Novartis’ Exforge To Launch By End Of June
Novartis’ Exforge To Launch By End Of June
Generic Norvasc May Launch Sooner Than Expected Following Appellate Court Ruling
Generic Norvasc May Launch Sooner Than Expected Following Appellate Court Ruling
FDA Review Of Novartis’ Tekturna Set Back Three Months
EMEA Issues Negative Opinion For Novartis’ Anti-Infective Mycograb
EMEA Issues Negative Opinion For Novartis’ Anti-Infective Mycograb
Galvus Review Delayed For Safety Analysis Of Primate Skin Data

Topics

Advertisement
UsernamePublicRestriction

Register

PS063593

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel